Heterogeneity of breast cancer among patients and implications for patient selection for adjuvant chemotherapy

被引：8

作者：

Andre, Fabrice ^{[1
]}

Pusztai, Lajos ^{[1
]}

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Dept Breast Med Oncol, Unit 1354, Houston, TX 77030 USA

来源：

PHARMACEUTICAL RESEARCH | 2006年 / 23卷 / 09期

关键词：

biomarker; breast cancer; chemotherapy; DNA microarrays; prognosis;

D O I：

10.1007/s11095-006-9075-5

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

Although the benefits of adjuvant chemotherapy are not controversial, the absolute effect of such therapy is small. Therefore, there is a need to identify biomarkers that can help select patients with localized breast cancer for treatment. Despite intense research in this field, no biomarker has been shown to be useful to predict benefit of adjuvant chemotherapy in daily practice. This can partially be explained by the fact that breast cancer is composed of several distinct subclasses, as shown by large-scale genomic analyses. In this review, we discuss why the current research approach based on a single biomarker is limited by the heterogeneity of cancer among patients. We then propose three solutions to improve the research strategies in this field: investigate one biomarker in a single homogeneous subclass to improve its predictive value; study the predictive value of multibiomarker assays in larger populations; and use functional pathways to predict the efficacy of a given drug.

引用

页码：1951 / 1958

页数：8

共 51 条

[1] High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses [J].

Abd El-Rehim, DM ;

Ball, G ;

Pinder, SE ;

Rakha, E ;

Paish, C ;

Robertson, JFR ;

Macmillan, D ;

Blamey, RW ;

Ellis, IO .

INTERNATIONAL JOURNAL OF CANCER, 2005, 116 (03) :340-350

[2]

Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0

[3] Reproducibility of gene expression signature-based predictions in replicate experiments [J].

Anderson, K ;

Hess, KR ;

Kapoor, M ;

Tirrel, S ;

Courtemanche, J ;

Wang, BL ;

Wu, Y ;

Gong, Y ;

Hortobagyi, GN ;

Symmans, WF ;

Pusztai, L .

CLINICAL CANCER RESEARCH, 2006, 12 (06) :1721-1727

[4] Correlation of p53 status with outcome of neoadjuvant chemotherapy using paclitaxel and doxorubicin in stage IIIB breast cancer [J].

Anelli, A ;

Brentani, RR ;

Gadelha, AP ;

de Albuquerque, AA ;

Soares, F .

ANNALS OF ONCOLOGY, 2003, 14 (03) :428-432

[5] Results of two randomized trials evaluating adjuvant anthracycline-based chemotherapy in 1 146 patients with early breast cancer [J].

Arriagada, R ;

Spielmann, M ;

Koscielny, S ;

Le Chevalier, T ;

Delozier, T ;

Rémé-Saumon, M ;

Ducourtieux, M ;

Tursz, T ;

Hill, C .

ACTA ONCOLOGICA, 2005, 44 (05) :458-466

[6] Gene Ontology: tool for the unification of biology [J].

Ashburner, M ;

Ball, CA ;

Blake, JA ;

Botstein, D ;

Butler, H ;

Cherry, JM ;

Davis, AP ;

Dolinski, K ;

Dwight, SS ;

Eppig, JT ;

Harris, MA ;

Hill, DP ;

Issel-Tarver, L ;

Kasarskis, A ;

Lewis, S ;

Matese, JC ;

Richardson, JE ;

Ringwald, M ;

Rubin, GM ;

Sherlock, G .

NATURE GENETICS, 2000, 25 (01) :25-29

[7] Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer [J].

Ayers, M ;

Symmans, WF ;

Stec, J ;

Damokosh, AI ;

Clark, E ;

Hess, K ;

Lecocke, M ;

Metivier, J ;

Booser, D ;

Ibrahim, N ;

Valero, V ;

Royce, M ;

Arun, B ;

Whitman, G ;

Ross, J ;

Sneige, N ;

Hortobagyi, GN ;

Pusztai, L .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (12) :2284-2293

[8] Standardizing global gene expression analysis between laboratories and across platforms [J].

Bammler, T ;

Beyer, RP ;

Bhattacharya, S ;

Boorman, GA ;

Boyles, A ;

Bradford, BU ;

Bumgarner, RE ;

Bushel, PR ;

Chaturvedi, K ;

Choi, D ;

Cunningham, ML ;

Dengs, S ;

Dressman, HK ;

Fannin, RD ;

Farun, FM ;

Freedman, JH ;

Fry, RC ;

Harper, A ;

Humble, MC ;

Hurban, P ;

Kavanagh, TJ ;

Kaufmann, WK ;

Kerr, KF ;

Jing, L ;

Lapidus, JA ;

Lasarev, MR ;

Li, J ;

Li, YJ ;

Lobenhofer, EK ;

Lu, X ;

Malek, RL ;

Milton, S ;

Nagalla, SR ;

O'Malley, JP ;

Palmer, VS ;

Pattee, P ;

Paules, RS ;

Perou, CM ;

Phillips, K ;

Qin, LX ;

Qiu, Y ;

Quigley, SD ;

Rodland, M ;

Rusyn, I ;

Samson, LD ;

Schwartz, DA ;

Shi, Y ;

Shin, JL ;

Sieber, SO ;

Slifer, S .

NATURE METHODS, 2005, 2 (05) :351-356

[9] Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy [J].

Bertheau, P ;

Plassa, F ;

Espié, M ;

Turpin, E ;

de Roquancourt, A ;

Marty, M ;

Lerebours, F ;

Beuzard, Y ;

Janin, A ;

de Thé, H .

LANCET, 2002, 360 (9336) :852-854

[10] HER-2/neu and topoisomerase IIα gene amplification and protein expression in invasive breast carcinomas -: Chromogenic in situ hybridization and immunohistochemical analyses [J].

Bhargava, R ;

Lal, P ;

Chen, BY .

AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2005, 123 (06) :889-895

← 1 2 3 4 5 6 →